Business Context and Reporting Period
Company: Insulet Corporation (NASDAQ: PODD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Insulet is a medical device company developing, manufacturing, and marketing the OmniPod Insulin Management System, a tubeless, wearable insulin infusion system for insulin-dependent diabetes. The system consists of a disposable OmniPod device and a handheld Personal Diabetes Manager (PDM). Commercial sales began in October 2005 in the U.S. In January 2010, the company entered an exclusive distribution agreement with Ypsomed for eleven international markets.
Key Financial Metrics (Year Ended Dec 31, 2009)
| Metric | 2009 | 2008 |
|---|---|---|
| Revenue | $66.0 million | $36.1 million |
| Cost of Revenue | $47.7 million | $40.6 million |
| Gross Profit | $18.3 million | ($4.6 million) loss |
| Gross Margin | 27.7% | (12.7%) |
| Operating Expenses | $77.7 million | $84.8 million |
| Operating Loss | ($59.4 million) | ($89.3 million) |
| Net Loss | ($79.5 million) | ($94.8 million) |
| Cash and Cash Equivalents | $128.0 million | $56.7 million |
| Working Capital | $134.5 million | $71.5 million |
| Long-Term Debt (Net) | $97.0 million | $60.2 million |
| Accumulated Deficit | ($329.9 million) | ($250.4 million) |
Note: 2008 figures have been restated to reflect the retrospective adoption of FASB ASC 470-20 regarding convertible debt.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 83% to $66.0 million, driven by an increase in the number of diabetes patients using the OmniPod System and expanded volume with third-party distributors.
- Gross Margin Improvement: The company achieved a positive gross profit of $18.3 million in 2009, compared to a gross loss of $4.6 million in 2008. This turnaround was achieved through increased manufacturing volumes, volume discounts on raw materials, and the transition of manufacturing to a contract manufacturer (Flextronics) in China.
- Operating Expenses: Total operating expenses decreased 8% to $77.7 million. Sales and marketing expenses declined 5% due to reduced spending on patient demonstration kits and advertising. Restructuring and impairment charges were $0 in 2009, compared to $8.2 million in 2008.
- Interest Expense: Net interest expense increased significantly to $20.2 million (from $5.4 million in 2008) due to the issuance of 5.375% Convertible Senior Notes and a Facility Agreement, as well as the amortization of debt discounts and non-cash charges related to debt extinguishment.
- Liquidity: Cash and cash equivalents more than doubled to $128.0 million, bolstered by a $66.1 million net proceeds from a public stock offering in October 2009 and proceeds from a Facility Agreement.
Guidance, Outlook, and Risks
- Outlook: Management expects revenue to continue to increase in 2010 due to new patient acquisition in the U.S. and expansion into international markets via the Ypsomed distribution agreement. The company anticipates continuing to incur net losses in the near term while focusing on reducing per-unit production costs and operating expenses.
- Liquidity Position: Management believes current cash, cash equivalents, and expected product sales will be sufficient to meet operating and debt service requirements through at least the end of 2010.
- Key Risks:
- Profitability: The company has incurred losses since inception and cannot assure it will achieve or sustain profitability. Profitability depends on reducing per-unit costs through increased volume.
- Reimbursement: Sales are heavily dependent on third-party payor reimbursement. Changes in reimbursement policies or denial of coverage could materially adversely affect revenue.
- Competition: The company faces intense competition from larger, well-capitalized companies (e.g., Medtronic, Animas, Roche) with greater resources and market share.
- Supply Chain: Reliance on third-party suppliers, including sole-source suppliers for key components and a single contract manufacturer in China, creates vulnerability to supply disruptions.
- Intellectual Property: Risks exist regarding patent infringement claims from competitors (e.g., Medtronic, Becton, Dickinson) and the ability to protect proprietary technology.
Investor Verification Checklist
- Reimbursement Status: Verify the status of Medicare coding verification and the success of private insurer contract negotiations, as these are critical for revenue sustainability.
- International Expansion: Monitor the timeline and reimbursement approvals for the Ypsomed distribution agreement in France, Germany, the UK, and other target markets.
- Debt Obligations: Review the terms of the $85 million Convertible Senior Notes (due 2013) and the $32.5 million Facility Agreement (due 2012), including interest rates and potential dilution from warrants.
- Manufacturing Costs: Track the per-unit cost of the OmniPod to ensure the company can maintain positive gross margins as sales volumes fluctuate.
- Patent Litigation: Monitor any developments regarding patent infringement discussions with Medtronic and Becton, Dickinson.